The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma
Official Title: A Phase I Open-label Study of the Safety and Immunogenicity of Escalating Doses of Lipovaxin-MM, a Novel Melanoma Immunotherapeutic, in Patients With Metastatic Melanoma
Study ID: NCT01052142
Brief Summary: The purpose of this study is to determine whether Lipovaxin-MM, a new anti-cancer vaccine, is safe and effective in improving the body's ability to destroy cancer cells in patients with metastatic melanoma.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Pain & Anaesthesia Research Clinic, Adelaide, South Australia, Australia
Name: Michael Brown, MBBS FRACP FRCPA
Affiliation: Royal Adelaide Hospital Cancer Centre
Role: PRINCIPAL_INVESTIGATOR